World Journal of Surgery

, Volume 32, Issue 11, pp 2375–2382 | Cite as

Surgical Margin Status and Prognosis of Gastrointestinal Stromal Tumor

  • António M. Gouveia
  • Amadeu P. Pimenta
  • Ana F. Capelinha
  • Dionísio de la Cruz
  • Paula Silva
  • José M. Lopes



Surgery is the best treatment for primary GIST and may be curative, but resection extension/completeness impact on the prognosis remains controversial. The authors aim was to evaluate the clinicopathological (CP) parameters and surgical margins status influence on GIST patients’ outcome.

Materials and methods

The study evaluated 113 consecutive patients with sporadic GIST; the influence of CP parameters on recurrence-free survival (RFS) and disease-specific survival (DSS) was determined by univariate analysis (UA) and multivariate analysis (MA).


Of 104 cases, macroscopically complete resection was achieved in 96: R0 surgical margin status in 78 and R1 in 18. Recurrence rates (12.5%) were significantly lower in R0 (9.0%) than in R1 (27.8%). Tumor >10 cm, mitotic count >5/50 high power field (HPF), and high-risk GIST predicted poor RFS and DSS (UA). Disease-specific survival was significantly shorter after macroscopic incomplete (R2) resection, for mixed cellular morphology, and in tumors with necrosis (UA). High-risk GIST (p = 0.016) and R2 resection (p = 0.013) predicted poor DSS of patients (MA).


High risk and positive macroscopic surgical margin status are parameters associated with poor disease-specific survival in GIST patients.


Overall Survival Imatinib Gastrointestinal Stromal Tumor Gist Patient Tumor Rupture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported in part by Novartis Oncology, Portugal.


  1. 1.
    Miettinen M, Blay JY, Sobin LH (2000) Mesenchymal tumors of the stomach. In: Hamilton SR, Aaltonen LA (eds) Pathology and genetics of tumors of the digestive system. Lyon, France, IARC Press, pp 62–65Google Scholar
  2. 2.
    Nilsson B, Bümming P, Meis-Kindblom JM et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 103:821–829PubMedCrossRefGoogle Scholar
  3. 3.
    Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1–12PubMedCrossRefGoogle Scholar
  4. 4.
    DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58PubMedCrossRefGoogle Scholar
  5. 5.
    Pierie JP, Choudry U, Muzikansky A et al (2001) The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136:383–389PubMedCrossRefGoogle Scholar
  6. 6.
    DeMatteo RP, Heinrich MC, El-Rifai WM et al (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33:466–477PubMedCrossRefGoogle Scholar
  7. 7.
    Roberts PJ, Eisenberg B (2002) Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 38(suppl 5):S37–S38PubMedCrossRefGoogle Scholar
  8. 8.
    Connolly E, Gaffney E, Reynolds J (2003) Gastrointestinal stromal tumors. Br J Surg 90:1178–1186PubMedCrossRefGoogle Scholar
  9. 9.
    Wu P, Langerman B, Ryan C et al (2003) Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 134:656–665PubMedCrossRefGoogle Scholar
  10. 10.
    Bucher P, Egger JF, Gervaz P et al (2006) An audit of surgical management of gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 32:310–314PubMedCrossRefGoogle Scholar
  11. 11.
    Bümming P, Ahlman H, Andersson J et al (2006) Population-based study of the diagnosis and treatment of gastrointestinal stromal tumors. Br J Surg 93:836–843PubMedCrossRefGoogle Scholar
  12. 12.
    Langer C, Gunawan B, Schuler P et al (2003) Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumors. Br J Surg 90:332–339PubMedCrossRefGoogle Scholar
  13. 13.
    Aparicio T, Boige V, Sabourin J et al (2004) Prognostic factors after surgery of primary respectable gastrointestinal stromal tumors. Eur J Surg Oncol 30:1098–1103PubMedCrossRefGoogle Scholar
  14. 14.
    Verreet PR, Clausing TA, Schoepp C (2000) Principles of surgical management of stromal tumor. Chirurg 71:1335–1344PubMedCrossRefGoogle Scholar
  15. 15.
    Eisenberg B, Judson I (2004) Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 11:465–475PubMedCrossRefGoogle Scholar
  16. 16.
    Lehnert T (1998) Gastrointestinal sarcoma (GIST)—a review of surgical management. Ann Chir Gynaecol 87:297–305PubMedGoogle Scholar
  17. 17.
    Hohenberger P, Reichardt P, Gebauer B et al (2004) Gastrointestinal stromal tumors (GIST)—current concepts of surgical management. Deutsch Med Wochenschr 129:1817–1820CrossRefGoogle Scholar
  18. 18.
    Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New YorkGoogle Scholar
  19. 19.
    Fletcher CDM, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465PubMedCrossRefGoogle Scholar
  20. 20.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  21. 21.
    Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29:52–68PubMedCrossRefGoogle Scholar
  22. 22.
    Tran T, Davila JA, El-Scrag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1, 458 cases from 1992 to 2000. Am J Gastroenterol 100:162–168PubMedCrossRefGoogle Scholar
  23. 23.
    Kindblom LG, Meis-Kindblom J, Bumming P et al (2003) Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST): a population-based study of 600 cases (abstract). Ann Oncol 13(suppl 5):157Google Scholar
  24. 24.
    Emory TS, Sobin LH, Lukes L et al (1999) Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 23:82–87PubMedCrossRefGoogle Scholar
  25. 25.
    Miettinen M, Lasota J (2003) Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 54:3–24PubMedGoogle Scholar
  26. 26.
    Horton KM, Juluru K, Montogomery E et al (2004) Computed tomography imaging of gastrointestinal stromal tumors with pathology correlation. Comput Assist Tomogr 28:811–817CrossRefGoogle Scholar
  27. 27.
    Hersh MR, Choi J, Garrett C et al (2005) Imaging gastrointestinal stromal tumors. Cancer Control 12:111–115PubMedGoogle Scholar
  28. 28.
    Gouveia AM, Pimenta AP, Lopes JM et al (2005) Esophageal GIST: therapeutic implications of an uncommon presentation of a rare tumor. Dis Esophagus 18:70–73PubMedCrossRefGoogle Scholar
  29. 29.
    DeMatteo RPRP, Maki RGRG, Antonescu CC et al (2003) Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Prob Surg 40:144–193CrossRefGoogle Scholar
  30. 30.
    Gomes AL, Gouveia A, Capelinha AF et al (2008) Molecular alterations of KIT and PDGFRA in GISTs. An evaluation study of a Portuguese series. J Clin Pathol 61:203–208PubMedCrossRefGoogle Scholar
  31. 31.
    Shiu MH, Farr GH, Papachristou DN et al (1982) Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 49:177–187PubMedCrossRefGoogle Scholar
  32. 32.
    McGrath PC, Neifeld JP, Lawrence WJ et al (1987) Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 206:706–710PubMedCrossRefGoogle Scholar
  33. 33.
    Ng EH, Pollock RE, Munsell MF et al (1992) Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215:68–77PubMedGoogle Scholar
  34. 34.
    Muro-Cacho CA, Cantor AB, Morgan M (2000) Prognostic factors in malignant gastrointestinal stromal tumors. Ann Clin Lab Sci 30:239–247PubMedGoogle Scholar
  35. 35.
    Crosby JA, Catton CN, Davis A et al (2001) Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 8:50–59PubMedCrossRefGoogle Scholar
  36. 36.
    Miettinen M, El-Rifai W, H L Sobin L et al. (2002) Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33:478–483Google Scholar
  37. 37.
    Lin S, Huang M, Zeng C et al (2003) Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. World Gastroenterol 9:2809–2812Google Scholar
  38. 38.
    Fujimoto Y, Nakanishi Y, Yoshimura K et al (2003) Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 6:39–48PubMedCrossRefGoogle Scholar
  39. 39.
    Wong NA, Young R, Malcomson RD et al (2003) Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 43:118–126PubMedCrossRefGoogle Scholar
  40. 40.
    Mochizuki Y, Kodera Y, Ito S et al (2004) Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach. World J Surg 28:870–875PubMedCrossRefGoogle Scholar
  41. 41.
    Wu TJ, Lee LY, Yeh CN et al (2006) Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate. BMC Gastroenterol 6:29PubMedCrossRefGoogle Scholar
  42. 42.
    Wardelmann E, Büttner R, Merkelbach-Bruse S et al (2007) Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 451:743–749PubMedCrossRefGoogle Scholar
  43. 43.
    Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813–3825PubMedCrossRefGoogle Scholar
  44. 44.
    Bucher P, Villiger P, Egger JF et al (2004) Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly 134:145–153PubMedGoogle Scholar
  45. 45.
    Samiian L, Weaver M, Velanovich V (2004) Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up. Am Surg 70:187–192PubMedGoogle Scholar
  46. 46.
    Chou FF, Eng HL, Sheen-Chen SM (1996) Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. Surgery 119:171–177PubMedCrossRefGoogle Scholar
  47. 47.
    Boni L, Benevento A, Dionigi G et al (2005) Surgical resection for gastrointestinal stromal tumors (GIST): experience on 25 patients. World J Surg Oncol 3:78PubMedCrossRefGoogle Scholar
  48. 48.
    He LJ, Wang BS, Chen CC (1988) Smooth muscle tumors of the digestive tract: report of 160 cases. Br J Surg 75:184–186PubMedCrossRefGoogle Scholar
  49. 49.
    Roy M, Sommers SC (1989) Metastatic potential of gastric leiomyosarcoma. Pathol Res Pract 185:874–877PubMedGoogle Scholar
  50. 50.
    Franquemont DW, Frierson HF Jr (1992) Muscle differentiation and clinicopathologic features of gastrointestinal stromal tumors. Am J Surg Pathol 16:947–954PubMedCrossRefGoogle Scholar
  51. 51.
    Pidhorecky I, Cheney RT, Kraybill WG et al (2000) Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7:705–712PubMedCrossRefGoogle Scholar
  52. 52.
    Rossi CR, Mocellin S, Mencarelli R et al (2003) Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 107:171–176PubMedCrossRefGoogle Scholar
  53. 53.
    Dougherty MJ, Compton C, Talbert M et al (1990) Sarcoma of the gastrointestinal tract. Ann Surg 214:569–574CrossRefGoogle Scholar
  54. 54.
    Lillemoe KD, Efron DT (2001) Gastrointestinal stromal tumors. In: Cameron JL, Gery L (eds) Current surgical therapy. St. Louis, Mosby, pp 112–117Google Scholar
  55. 55.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056PubMedCrossRefGoogle Scholar
  56. 56.
    van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 358:1421–1423PubMedCrossRefGoogle Scholar
  57. 57.
    Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRefGoogle Scholar
  58. 58.
    Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134PubMedCrossRefGoogle Scholar
  59. 59.
    DeMatteo RP (2002) The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 9:831–839PubMedCrossRefGoogle Scholar
  60. 60.
    Bümming P, Andersson J, Meis-Kindblom JM et al (2003) Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 89:460–464PubMedCrossRefGoogle Scholar
  61. 61.
    Nilsson B, Sjölund K, Kindblom LG et al (2007) Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 96:1656–1658PubMedCrossRefGoogle Scholar
  62. 62.
    Trupiano J, Stewart R, Misick C et al (2002) Gastric stromal tumors, a clinicopathological study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviour. Am J Surg Pathol 26:705–714PubMedCrossRefGoogle Scholar
  63. 63.
    Sanders L, Silverman M, Rossi R et al (1996) Gastric smooth muscle tumors: diagnostic dilemmas and factors affecting outcome. World J Surg 20:992–995PubMedCrossRefGoogle Scholar
  64. 64.
    Ludwig DJ, Traverso LW (1997) Gut stromal tumors and their clinical behavior. Am J Surg 173:390–394PubMedCrossRefGoogle Scholar
  65. 65.
    Miettinen M, Sarlomo-Rikala M, Lasota J (1999) Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 30:1213–1220PubMedCrossRefGoogle Scholar
  66. 66.
    Bucher P, Taylor S, Villiger P et al (2004) For small intestinal stromal tumors are there prognostic factors. Am J Surg 187:761–766PubMedCrossRefGoogle Scholar
  67. 67.
    Mudan SS, Conlon KC, Woodruff JM et al (2000) Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 88:66–74PubMedCrossRefGoogle Scholar
  68. 68.
    Pross M, Manger T, Schulz HU et al (1999) Gastrointestinal stromal tumors—problems in diagnosis and therapy. Chirurg 70:807–812PubMedCrossRefGoogle Scholar
  69. 69.
    Heinrich MC, Corless CL (2005) Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. J Surg Oncol 90:195–207PubMedCrossRefGoogle Scholar
  70. 70.
    Demetri GD, Baker LH, Benjamin RS et al (2007) Soft tissue sarcoma. J Natl Compr Cancer Netw 5:364–399Google Scholar
  71. 71.
    Yan H, Marchettini P, Acherman YI et al (2003) Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 26:221–228PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2008

Authors and Affiliations

  • António M. Gouveia
    • 1
    • 2
  • Amadeu P. Pimenta
    • 1
    • 2
  • Ana F. Capelinha
    • 3
  • Dionísio de la Cruz
    • 3
  • Paula Silva
    • 2
    • 3
  • José M. Lopes
    • 2
    • 3
  1. 1.Department of SurgeryHospital de S. João/Porto Medical SchoolPortoPortugal
  2. 2.Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP)PortoPortugal
  3. 3.Department of PathologyHospital de S. João/Porto Medical SchoolPortoPortugal

Personalised recommendations